Optimized procedures for testing plasma metanephrines in patients on hemodialysis.
Adrenal Gland Neoplasms
/ blood
Aged
Aged, 80 and over
Blood Chemical Analysis
/ methods
Blood Specimen Collection
/ methods
Calibration
Dopamine
/ analogs & derivatives
Female
Humans
Male
Metanephrine
/ analysis
Middle Aged
Paraganglioma
/ blood
Pheochromocytoma
/ blood
Poland
Pre-Analytical Phase
/ methods
Reference Values
Renal Dialysis
Tandem Mass Spectrometry
/ methods
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
19 07 2021
19 07 2021
Historique:
received:
22
04
2021
accepted:
05
07
2021
entrez:
20
7
2021
pubmed:
21
7
2021
medline:
1
12
2021
Statut:
epublish
Résumé
Diagnosis of pheochromocytomas and paragangliomas in patients receiving hemodialysis is troublesome. The aim of the study was to establish optimal conditions for blood sampling for mass spectrometric measurements of normetanephrine, metanephrine and 3-methoxytyramine in patients on hemodialysis and specific reference intervals for plasma metanephrines under the most optimal sampling conditions. Blood was sampled before and near the end of dialysis, including different sampling sites in 170 patients on hemodialysis. Plasma normetanephrine concentrations were lower (P < 0.0001) and metanephrine concentrations higher (P < 0.0001) in shunt than in venous blood, with no differences for 3-methoxytyramine. Normetanephrine, metanephrine and 3-methoxytyramine concentrations in shunt and venous blood were lower (P < 0.0001) near the end than before hemodialysis. Upper cut-offs for normetanephrine were 34% lower when the blood was drawn from the shunt and near the end of hemodialysis compared to blood drawn before hemodialysis. This study establishes optimal sampling conditions using blood from the dialysis shunt near the end of hemodialysis with optimal reference intervals for plasma metanephrines for the diagnosis of pheochromocytomas/paragangliomas among patients on hemodialysis.
Identifiants
pubmed: 34282182
doi: 10.1038/s41598-021-94104-9
pii: 10.1038/s41598-021-94104-9
pmc: PMC8290036
doi:
Substances chimiques
Metanephrine
5001-33-2
3-methoxytyramine
JCH2767EDP
Dopamine
VTD58H1Z2X
Types de publication
Clinical Trial
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
14706Informations de copyright
© 2021. The Author(s).
Références
Clin Endocrinol (Oxf). 2014 Apr;80(4):478-86
pubmed: 24102244
Kidney Int. 2004 May;65(5):1568-76
pubmed: 15086894
J Clin Endocrinol Metab. 1982 Aug;55(2):263-8
pubmed: 7085853
Am J Kidney Dis. 2004 May;43(5):e17-22
pubmed: 15112194
J Clin Endocrinol Metab. 1995 Oct;80(10):3009-17
pubmed: 7559889
Am J Physiol. 1994 Sep;267(3 Pt 1):E380-7
pubmed: 7943218
Kidney Int. 2005 Feb;67(2):668-77
pubmed: 15673315
Kidney Int. 1987 Jan;31(1):107-11
pubmed: 3560639
Clin Sci (Lond). 1995 May;88(5):533-42
pubmed: 7614812
N Engl J Med. 1992 Dec 31;327(27):1912-8
pubmed: 1454086
Endocrinol Metab Clin North Am. 1993 Jun;22(2):329-41
pubmed: 8325290
Ann Clin Biochem. 1999 Sep;36 ( Pt 5):587-91
pubmed: 10505207
Ann Clin Biochem. 2014 Jan;51(Pt 1):38-46
pubmed: 23873873
Endocr Pract. 2014 Feb;20(2):139-44
pubmed: 24014007
Am J Nephrol. 1995;15(2):147-51
pubmed: 7733152
Am J Kidney Dis. 2002 Nov;40(5):974-82
pubmed: 12407642
Psychosom Med. 1987 Nov-Dec;49(6):591-605
pubmed: 2827219
Pharmacol Ther. 2001 Jul;91(1):35-62
pubmed: 11707293
J Pharmacol Exp Ther. 2003 Jun;305(3):800-11
pubmed: 12649306
Eur J Endocrinol. 2017 Aug;177(2):103-113
pubmed: 28476870
Am J Kidney Dis. 2018 Dec;72(6):907-909
pubmed: 30146420
J Clin Endocrinol Metab. 2014 Jun;99(6):1915-42
pubmed: 24893135
Clin Chem. 2015 Jul;61(7):993-6
pubmed: 25931454
Lancet. 2005 Aug 20-26;366(9486):665-75
pubmed: 16112304